Skip to main content

Table 1 HNSCC, definitive radio- radiochemotherapy by PSMD1-score

From: Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients

PSMD1-score

1 (n=29)

2 (n=26)

3 (n=27)

Age (years) mean

59.5

62.1

59.3

Q1/Q2/Q3

54/59/65

56/61.5/69.7

55/60/63

Male (%)

96.5

84.6

92.5

Weight (kg) mean

72.7

72.0

71.7

Q1/Q2/Q3

60/67/81

61.5/66/79

64.5/72/80

Smoker (n)

17/26

19/24

20/26

Karnofski >= 70 (n)

11/13

8/8

6/7

Hemoglobin level (mg/dL) mean

12.7

13.5

13.2

Q1/Q2/Q3

11.9/12.9/14

12.8/13.7/14.1

12.4/13.5/14.4

Oral cavity n (%)

4 (13.7)

3 (11.5)

5 (18.5)

Oropharynx n (%)

13 (44.8)

9 (34.5)

9 (33.3)

Hypopharynx n (%)

10 (34.4)

11 (42.2)

8 (29.6)

Larynx n (%)

2 (6.8)

3 (11.5)

5 (18.5)

cT1 n (%)

1 (3.4)

1 (3.8)

 

cT2 n (%)

2 (6.8)

3 (11.5)

4 (14.8)

cT3 n (%)

11 (37.9)

6 (23.0)

7 (25.9)

cT4 n (%)

15 (51.7)

16 (61.5)

16 (59.2)

cN0 n (%)

2 (6.8)

4 (15.3)

3 (11.1)

cN1 n (%)

6 (20.6)

1 (3.8)

1 (3.7)

cN2 n (%)

19 (65.3)

20 (76.8)

21 (57.7)

cN3 n (%)

2 (6.9)

1 (3.8)

2 (7.4)

G1 n (%)

2 (6.8)

2 (7.6)

 

G2 n (%)

12 (41.3)

17 (65.3)

14 (53.8)

G3 n (%)

15 (51.7)

7 (26.9)

12 (46.1)

EpoR (C20+) (%)

19 (65.5)

18 (69.2)

22 (81.4)

RT (Gy) mean

71.1

69.7

67.7

Q1/Q2/Q3

70/70.6/72

69.9/70/70.6

70/70/70.6

RT (days)

48.1

47.5

45.0

Q1/Q2/Q3

42.5/48/52

42/45.5/51

42/45/50

treated in study A1/B2/C3/D4 (n)

1/10/14/4

3/10/7/6

4/13/6/4

Local control (months) median

18.3

nr

nr

Survival (months) median; 95% CI

21.2; 10.5-28.7

28.8; 6.3-42.4

43.8; 12.4-